

Generex Biotechnology Appoints Omar Gzouli to the Board of Directors

Investment Banking Executive Brings Global Expertise in Corporate Finance and M&A

MIRAMAR, FL, April 8, 2019 - Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (<http://www.otcm Markets.com/stock/GNBT/quote>) is proud to announce the appointment of Omar Gzouli to the Board of Directors as a non-executive member. Mr. Gzouli is a global Finance Executive with a distinguished Investment Banking career in New York and London. Currently, he is a Partner and Portfolio Manager at a London, UK based alternatives investments firm.

Previously, Mr. Gzouli was a Managing Director in Equity Derivatives at Barclays Investment Bank, London, UK where he was Global Head of Trading for the Equity and Funds Structured markets unit. In his time at Barclays, he was also Head of Equity Financing for Europe and Asia.

Mr. Gzouli started his Investment Banking career at Lehman Brothers in New York, NY where he became a Managing Director on the U.S. Equity Structured Products Desk, leading the Trading team.

Mr. Gzouli earned a Diplome d'Ingénieur in Applied Mathematics from Ecole Centrale Paris. He received his Masters of Science degree in Operations Research from the MIT Sloan School of Management.

“Omar Gzouli is an exceptional addition to our Board of Directors,” said Joseph Moscato, President & CEO of Generex Biotechnology. “He brings a wealth of experience in global investment banking and finance fulfilling an important need on our Board. I have known Omar for a number of years, and can attest to his knowledge of life science investment, corporate finance, and mergers & acquisitions. We look forward to his guidance in building Generex as an integrated life science holding company.”

About Generex Biotechnology Corp.

Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care.

In addition to advancing a legacy portfolio of immune-oncology assets, medical devices, and diagnostics, the Company is focused on an acquisition strategy of strategic businesses that complement existing assets and provide immediate sources of revenue and working capital. Recent acquisitions include a management services organization, a network of pharmacies, clinical laboratory, and medical device companies with new and approved products.

Our newly formed, wholly-owned subsidiary, NuGenerex Distribution Solutions (NDS), integrates our MSO network with a pharmacy network, clinical diagnostic lab, durable medical equipment company (DME-IQ) and dedicated call center.

Cautionary Note Regarding Forward-Looking Statements

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

Generex Contact:

Generex Biotechnology Corporation

Joseph Moscato

646-599-6222

Todd Falls

1-800-391-6755 Extension 222

investor@generex.com